Form 4: Caribou Biosciences Director Acquires Options to Purchase 40,500 Shares

Director Nancy Whiting acquired options to purchase 40,500 shares of Caribou Biosciences common stock at an exercise price of $1.41 on February 20, 2025.

Summary

• On February 20, 2025, Nancy Whiting, a director of Caribou Biosciences, Inc., acquired an option to purchase 40,500 shares of the company's common stock.
• The exercise price of the option is $1.41 per share.
• The option vests in equal monthly installments over a year, starting from the grant date, and will be fully vested on February 20, 2026, contingent upon continued service to the Issuer.
• The expiration date of the option is February 19, 2035.
• Following the transaction, Whiting directly owns options for 40,500 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a stock option grant to a director. The grant itself can be seen as mildly positive, reflecting confidence, but the filing is primarily informational.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their holdings in the company's stock.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry to align their interests with those of shareholders.
• The vesting schedule of one year is fairly standard for such grants.
• The exercise price of $1.41 would need to be compared to the market price of CRBU stock at the time of the grant to assess its favorability.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of director confidence.
• The impact on employees, customers, suppliers, and creditors is likely negligible.

Key Dates

Keywords

Caribou Biosciences, CRBU, stock options, director, Nancy Whiting, Form 4, beneficial ownership, equity securities